Prima Biomed and Bioceros announce licensing agreement for Cripto-1 cancer immunotherapy treatment
Prima BioMed Ltd announced that its subsidiary company, Oncomab Pty Ltd has entered into a licensing agreement for the development of a Cripto-1 cancer monoclonal antibody (mAB) with Bioceros. The licensing agreement paves the way for the further development of Oncomab’s technology to create a Cripto-1 mAB as an immunotherapy treatment for cancers.
Cripto-1 is a protein found in high levels on the surface of a number of different types of malignant tumour cells. It facilitates growth of the tumor cells, and contributes to their spreading throughout the body. The antibody works by binding to the Cripto-1 molecule interfering with local development of the tumor, and preventing distant seeding of tumor cells.
The antibody may be administered in combination with cytotoxic drugs (chemotherapy drugs) to create an even more lethal potent additive effect on tumour cell destruction. The Licensing Agreement with Bioceros is by way of a 70 (Prima):30 (Bioceros) project split, and the work will be undertaken by Bioceros.
Prima’s agreement, through Oncomab, for the out-licensing and development of Cripto-1 expands the Company’s clinical development programs in the area of immunotherapy cancer treatments.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
